Carfilzomib has an important date next week.

An advisory committee to the U.S. Food and Drug Administration (FDA) will meet next Wednesday to review data about car­filz­o­mib's efficacy and safety.  The review will focus, in particular, on clinical trial results for carfilzomib (Kyprolis) as a treat­ment for re­lapsed and refractory multiple myeloma patients.

At the end of the meeting, the committee will vote whether or not to recommend that the FDA approve car­filz­o­mib as a new myeloma …

Interim results from three clinical trials suggest that MLN9708, as a single agent or in com­bi­na­tion with Revlimid and dexa­meth­a­sone, may be an effective and well tolerated treat­ment for both pre­vi­ously untreated multiple myeloma patients and patients with re­lapsed or refractory disease.

Findings from the three trials were presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago earlier this month.

According to Dr. Irene Ghobrial from the Dana Farber Cancer Institute in Boston, who presented a …

This spring, my choir is performing a tribute concert to Queen Elizabeth II for her Diamond Jubilee.  Thus, many of the songs we sing originate in the U.K.  One song by the Beatles, which has a rollicking beat, barbershop in nature, is called ‘When I’m Sixty-Four.’

During one of our recent rehearsals, I suddenly realized that the first line of the song...’When I get older, losing my hair, many years from now…,’ had already applied to me.  I had already …

Multiple myeloma physicians and researchers are gathering at the 17^th Congress of the European Hematology Association (EHA) to share the latest findings in the field. The meeting started today in Amsterdam and will run through Sunday, June 17.

The Myeloma Beacon will report on the most important myeloma-related findings from the meeting over the next couple of weeks.

The research presented at the meeting will cover all areas of hematology, which is the study of blood, blood-forming organs, and blood-related …

Elotuzumab in com­bi­na­tion with Revlimid and dexa­meth­a­sone con­tinues to show prom­ise in re­lapsed and re­frac­tory myeloma patients, ac­cord­ing to up­dated re­­sults from an on­go­ing Phase 2 clin­i­cal trial.

Response rates con­tinued to be high, par­tic­u­larly among study par­tic­i­pants re­ceiv­ing the lower elotuzumab dose.  In addi­tion, the rate of severe side effects remained low.

Dr. Philippe Moreau from the Uni­ver­sity Hospital in Nantes, France, pre­sented the re­­sults last Monday at the 48th annual meeting of the American Society of Clinical Oncology …

It was one heck of a gorgeous Sunday afternoon in the Ozarks back in the spring of 2009. In fact, it was the kind of picture-post-card day that you like to file away in your memory.

But what I had no way of knowing was that a would-be killer, lurking nearby, was ready to ruin my perfectly good day by striking out at me when I least expected it.

Having been out of state for four months of aggressive treatment …

Yesterday was a rainy Sunday in Georgia – the kind of day that’s perfect for an afternoon nap, or a movie marathon.  For me, it was a very rare day, one with nothing on my agenda.  So, it was a great time for puttering around the house.

In attempting to clean my home office, which honestly is approaching the type of chaos seen on “Hoarders,” I came across many multiple myeloma articles and other cancer-related clippings gathered since my sister …